Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
When sinus surgery no longer controls polyps and inflammation, targeted biologics such as dupilumab or omalizumab can offer a less invasive way to block key immune signals and reduce symptoms within weeks to months. A proper pre therapy workup, coordination among your ENT, allergist, and primary care provider, insurance clearance, and injection training are all essential next steps.
There are several other important considerations including side effect monitoring, cost, lifestyle measures, and follow up schedules: see below for complete details to guide your healthcare journey.
Chronic sinus inflammation and nasal polyps can significantly impact your quality of life. When sinus surgery doesn't provide lasting relief—or if inflammation returns—you and your doctor may consider switching from sinus surgery to targeted biologics. This guide explains the reasons behind this shift, outlines what you need to know, and helps you take practical next steps toward better symptom control.
Patients and physicians may opt for targeted biologics after sinus surgery for several key reasons:
Recurrence of Nasal Polyps
Polyps often regrow even after technically successful surgeries, leading to repeated operations.
Persistent Inflammation
Ongoing immune activity in the sinuses can cause swelling, congestion, and pain despite good surgical outcomes.
Surgery-Related Complications
Scar tissue, bleeding, or changes in sinus anatomy may limit the effectiveness of additional procedures.
Desire for Less Invasive Treatment
Biologics are injected medications, avoiding general anesthesia, postoperative recovery, and potential surgical risks.
Associated Asthma or Atopic Conditions
Many adults with recurrent sinus issues also have asthma, eczema, or allergic rhinitis. Biologics can address multiple inflammation pathways at once.
Targeted biologics are advanced medications designed to block specific molecules in your immune system that drive chronic inflammation. Common features include:
Mechanism of Action
Biologics target interleukins (for example, IL-4, IL-5, IL-13) or immunoglobulin E (IgE) to reduce mucus production, swelling, and polyp growth.
FDA-Approved Options
Examples include dupilumab, omalizumab, and mepolizumab. Your specialist will choose based on your disease profile.
Administration
Most are given as subcutaneous (under-the-skin) injections every 2–8 weeks, which you can often do at home.
Before making the switch, your medical team will confirm that targeted therapy is a good fit:
A coordinated approach ensures the best outcomes:
Be open about your treatment goals, lifestyle, and any concerns you have about injections or side effects.
When planning the transition, keep these factors in mind:
Results vary, but many patients notice benefits within weeks to months:
Biologics work best alongside simple at-home routines:
Before your next appointment to discuss switching to biologics, it's helpful to document all your current symptoms, their frequency, and how they're affecting your daily life. To make this easier, you can use Ubie's free Medically Approved LLM Symptom Checker Chat Bot to organize your symptoms and generate a comprehensive overview that will help you have a more productive conversation with your healthcare team about whether targeted biologics are right for you.
Although biologics are generally safe, always contact a healthcare professional if you experience:
For any life-threatening or serious concerns, call emergency services or go to the nearest hospital.
Switching from sinus surgery to targeted biologics can offer significant relief when surgery alone isn't enough. By working closely with your healthcare team, staying informed, and keeping up with treatments and lifestyle measures, you'll be well on your way to better sinus health. Always speak with your doctor about any serious or life-threatening symptoms.
(References)
* Doshi J, Patel SN, Ramakrishnan VR. Biologics for Chronic Rhinosinusitis with Nasal Polyps: Indications and Considerations for Use in the Surgical Patient. Otolaryngol Clin North Am. 2023 Oct;56(5):949-960. doi: 10.1016/j.otc.2023.05.006. Epub 2023 Jul 11. PMID: 37626915.
* Dinh CT, Smith TL. Medical vs. Surgical Therapy for Chronic Rhinosinusitis: Is There a Shift in the Paradigm? Curr Otorhinolaryngol Rep. 2022 Dec;10(4):216-222. doi: 10.1007/s40136-022-00438-2. Epub 2022 Aug 3. PMID: 35921021; PMCID: PMC9347575.
* Takwoingi Y, Adal A, Hopkins C, Surda P. Role of biologics in the postsurgical management of chronic rhinosinusitis with nasal polyps. Curr Opin Otolaryngol Head Neck Surg. 2021 Jun 1;29(3):214-220. doi: 10.1097/MOO.0000000000000726. PMID: 34005825.
* Al-Brahim Y, Bada G, Tsetsos D, Al-Brahim K, Soler ZM, Psaltis AJ. The Future of Biologics in Chronic Rhinosinusitis. Rhinology. 2023 Oct 1;61(5):378-386. doi: 10.4193/Rhin23.109. PMID: 37092301.
* Chaaban MR, Soler ZM. Biologics for the Treatment of Chronic Rhinosinusitis With Nasal Polyps: Are They the Future Standard of Care? Ann Otol Rhinol Laryngol. 2023 Sep;132(9):1042-1049. doi: 10.1177/00034894231168512. Epub 2023 Mar 28. PMID: 36979247.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.